Cover Image
市場調查報告書

Affimed Therapeutics AG - 產品平台檢討

Affimed Therapeutics AG - Product Pipeline Review - 2015

出版商 Global Markets Direct 商品編碼 224701
出版日期 內容資訊 英文 25 Pages
訂單完成後即時交付
價格
Back to Top
Affimed Therapeutics AG - 產品平台檢討 Affimed Therapeutics AG - Product Pipeline Review - 2015
出版日期: 2015年03月26日 內容資訊: 英文 25 Pages
簡介

Affimed Therapeutics AG 是配合臨床病期之生物科技企業,除了癌症以外,更開發治療發炎疾病等攸關生命的重病所用之獨家抗體藥。

本報告提供Affimed Therapeutics AG的治療藥開發平台現狀及各開發階段比較分析,提供您藥物標的,作用機制,給藥途徑,各分子類型的治療藥評估,最新的企業新聞和發表,後期階段及中止的計劃等相關資訊。

Affimed Therapeutics AG的基本資料

Affimed Therapeutics AG概要

  • 主要資訊
  • 企業資料

Affimed Therapeutics AG:R&D概要

  • 主要的治療範圍

Affimed Therapeutics AG:開發平台評估

  • 各開發階段的開發中產品
  • 單劑產品

Affimed Therapeutics AG:開發中產品概況

Affimed Therapeutics AG

  • 臨床實驗階段的開發中產品
    • 第二階段的產品/聯合治療模式
    • 第一階段的產品/聯合治療模式

Affimed Therapeutics AG

  • 初期階段的開發中產品
    • 藥物研發中的產品/聯合治療模式

Affimed Therapeutics AG:藥物簡介

  • FM-13
  • AFM-11
  • AFM-21

Affimed Therapeutics AG:開發平台分析

  • 標的別
  • 各給藥途徑
  • 各分子類型
  • 各作用機制

Affimed Therapeutics AG:最近的開發平台趨勢

Affimed Therapeutics AG:暫停中的計劃

Affimed Therapeutics AG:總公司和子公司的所在地

附錄

圖表

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: GMDHC06888CDB

Summary

Global Markets Direct's, 'Affimed Therapeutics AG - Product Pipeline Review - 2015', provides an overview of the Affimed Therapeutics AG's pharmaceutical research and development focus.

This report provides comprehensive information on the current therapeutic developmental pipeline of Affimed Therapeutics AG's, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews latest updates, and featured news and press releases, along with special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

  • The report provides brief overview of Affimed Therapeutics AG including business description, key information and facts, and its locations and subsidiaries
  • The report reviews current pipeline of Affimed Therapeutics AG's human therapeutic division and enlists all their major and minor projects
  • The report features product description and descriptive mechanism of action for key pipeline products along with the product's developmental history and major milestones
  • Special feature on out-licensed and partnered product portfolio
  • The report summarizes all the dormant and discontinued pipeline projects
  • Latest company statement
  • Latest news and deals relating to the Affimed Therapeutics AG's pipeline products

Reasons to buy

  • Evaluate Affimed Therapeutics AG's strategic position with total access to detailed information on its product pipeline
  • Assess the growth potential of Affimed Therapeutics AG in its therapy areas of focus
  • Identify new drug targets and therapeutic classes in the Affimed Therapeutics AG's R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas
  • Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps
  • Develop strategic initiatives by understanding the focus areas of Affimed Therapeutics AG and exploit collaboration and partnership opportunities
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Plan mergers and acquisitions effectively by identifying the most promising pipeline of Affimed Therapeutics AG
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
  • Explore the dormant and discontinued projects of Affimed Therapeutics AG and identify potential opportunities in those areas
  • Avoid Intellectual Property Rights related issues

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Affimed Therapeutics AG Snapshot
    • Affimed Therapeutics AG Overview
    • Key Information
    • Key Facts
  • Affimed Therapeutics AG - Research and Development Overview
    • Key Therapeutic Areas
  • Affimed Therapeutics AG - Pipeline Review
    • Pipeline Products by Stage of Development
    • Pipeline Products - Monotherapy
  • Affimed Therapeutics AG - Pipeline Products Glance
    • Affimed Therapeutics AG - Clinical Stage Pipeline Products
      • Phase II Products/Combination Treatment Modalities
      • Phase I Products/Combination Treatment Modalities
    • Affimed Therapeutics AG - Early Stage Pipeline Products
      • Preclinical Products/Combination Treatment Modalities
  • Affimed Therapeutics AG - Drug Profiles
    • AFM-13
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • AFM-11
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • AFM-21
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Monoclonal Antibodies for Multiple Myeloma
      • Product Description
      • Mechanism of Action
      • R&D Progress
  • Affimed Therapeutics AG - Pipeline Analysis
    • Affimed Therapeutics AG - Pipeline Products by Target
    • Affimed Therapeutics AG - Pipeline Products by Route of Administration
    • Affimed Therapeutics AG - Pipeline Products by Molecule Type
    • Affimed Therapeutics AG - Pipeline Products by Mechanism of Action
  • Affimed Therapeutics AG - Recent Pipeline Updates
  • Affimed Therapeutics AG - Dormant Projects
  • Affimed Therapeutics AG - Locations And Subsidiaries
    • Head Office
    • Other Locations & Subsidiaries
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
    • Disclaimer

List of Tables

  • Affimed Therapeutics AG, Key Information
  • Affimed Therapeutics AG, Key Facts
  • Affimed Therapeutics AG - Pipeline by Indication, 2015
  • Affimed Therapeutics AG - Pipeline by Stage of Development, 2015
  • Affimed Therapeutics AG - Monotherapy Products in Pipeline, 2015
  • Affimed Therapeutics AG - Phase II, 2015
  • Affimed Therapeutics AG - Phase I, 2015
  • Affimed Therapeutics AG - Preclinical, 2015
  • Affimed Therapeutics AG - Pipeline by Target, 2015
  • Affimed Therapeutics AG - Pipeline by Route of Administration, 2015
  • Affimed Therapeutics AG - Pipeline by Molecule Type, 2015
  • Affimed Therapeutics AG - Pipeline Products by Mechanism of Action, 2015
  • Affimed Therapeutics AG - Recent Pipeline Updates, 2015
  • Affimed Therapeutics AG - Dormant Developmental Projects,2015
  • Affimed Therapeutics AG, Subsidiaries

List of Figures

  • Affimed Therapeutics AG - Pipeline by Top 10 Indication, 2015
  • Affimed Therapeutics AG - Pipeline by Stage of Development, 2015
  • Affimed Therapeutics AG - Monotherapy Products in Pipeline, 2015
  • Affimed Therapeutics AG - Pipeline by Top 10 Target, 2015
  • Affimed Therapeutics AG - Pipeline by Top 10 Route of Administration, 2015
  • Affimed Therapeutics AG - Pipeline by Top 10 Molecule Type, 2015
  • Affimed Therapeutics AG - Pipeline Products by Top 10 Mechanism of Action, 2015
Back to Top